Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells

被引:52
作者
Elstner, Anja
Holtkamp, Nikola
von Deimling, Andreas
机构
[1] Univ Heidelberg Hosp, Dept Neuropathol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg Hosp, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany
[3] German Canc Res Ctr, D-69120 Heidelberg, Germany
关键词
glioblastoma; invasion; DFO; iron; Hif-1;
D O I
10.1007/s10585-007-9057-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Glioblastoma multiforme are highly invasive brain tumors. Experimental approaches focus on unravelling the mechanisms of invasion, this being a major reason for the poor prognosis of these tumors. Our previous results hinted towards involvement of the iron metabolism in invasion. In this study, we examined the effect of iron depletion on the invasive phenotype of glioblastoma cells. Transwell Matrigel invasion assays were used to monitor iron-dependent invasion of human glioblastoma cell lines U373MG and DBTRG05MG. Intracellular iron concentrations were modulated by applying desferrioxamine (DFO) and ferric ammonium citrate (FAC). We detected enhanced invasion of glioblastoma cells upon DFO-induced iron depletion. Treatment of cells with FAC strongly inhibited invasion. DFO treatment resulted in hypoxia-inducible factor 1 (Hif-1)-mediated induction of urokinase plasminogen activator receptor and matrix metalloproteinase 2. Further, RNA interference-mediated repression of urokinase plasminogen activator receptor inhibited DFO-induced invasion. Our data demonstrate a direct effect of DFO on Hif-1 expression resulting in activation of factors associated with ECM degradation and invasion of glioma cells. These findings caution on utilization of DFO and other iron chelators in the treatment of tumors with invasive potential.
引用
收藏
页码:57 / 66
页数:10
相关论文
共 47 条
[1]
Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells [J].
Ameri, K ;
Lewis, CE ;
Raida, M ;
Sowter, H ;
Hai, TW ;
Harris, AL .
BLOOD, 2004, 103 (05) :1876-1882
[2]
BECTON DL, 1988, CANCER RES, V48, P7189
[3]
Beerepoot LV, 1996, CANCER RES, V56, P3747
[4]
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population [J].
Brat, DJ ;
Castellano-Sanchez, AA ;
Hunter, SB ;
Pecot, M ;
Cohen, C ;
Hammond, EH ;
Devi, SN ;
Kaur, B ;
Van Meir, EG .
CANCER RESEARCH, 2004, 64 (03) :920-927
[5]
Iron chelators in cancer chemotherapy [J].
Buss, JL ;
Greene, BT ;
Turner, J ;
Torti, FM ;
Torti, SV .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (15) :1623-1635
[6]
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia [J].
Cappellini, MD ;
Cohen, A ;
Piga, A ;
Bejaoui, M ;
Perrone, S ;
Agaoglu, L ;
Aydinok, Y ;
Kattamis, A ;
Kilinc, Y ;
Porter, J ;
Capra, M ;
Galanello, R ;
Fattoum, S ;
Drelichman, G ;
Magnano, C ;
Verissimo, M ;
Athanassiou-Metaxa, M ;
Giardina, P ;
Kourakli-Symeonidis, A ;
Janka-Schaub, G ;
Coates, T ;
Vermylen, C ;
Olivieri, N ;
Thuret, I ;
Opitz, H ;
Ressayre-Djaffer, C ;
Marks, P ;
Alberti, D .
BLOOD, 2006, 107 (09) :3455-3462
[7]
Desferoxamine (DFO) - mediated iron chelation: rationale for a novel approach to therapy for brain cancer [J].
Dayani, PN ;
Bishop, MC ;
Black, K ;
Zeltzer, PM .
JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (03) :367-377
[8]
Donfrancesco A, 1995, ANTICANCER RES, V15, P2347
[9]
ESTROV Z, 1987, BLOOD, V69, P757
[10]
Furukawa K, 2006, INT J ONCOL, V29, P73